Pharming (PHAR) Research & Development (2020 - 2026)
Pharming's (PHAR) quarterly Research & Development came in at -$57.8 million in Q2 2026, down 28.95% YoY from -$81.4 million in Q2 2025, and down 126.24% on a QoQ basis from -$25.6 million in Q1 2026.
Pharming (PHAR) Research & Development (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Research & Development data on file, last reported at -$57.8 million in Q2 2026.
- Quarterly Research & Development fell 28.95% year-over-year to -$57.8 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$183.7 million (down 23.21% YoY) and the FY2025 annual result came in at $100.4 million, up 20.78% from the prior year.
- Research & Development eased to -$57.8 million in Q2 2026, from -$25.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$20.7 in Q3 2024 to a low of -$100.4 million in Q4 2025.
- A 5-year average of -$30.8 million and a median of -$20.9 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 100.0% in 2024, down 191952053.11% in 2024.
- Tracing PHAR's Research & Development over 5 years: stood at -$52.5 million in 2022, then soared by 100.0% to -$57.3 in 2023, then sank by 145108102.44% to -$83.1 million in 2024, then slipped by 20.71% to -$100.4 million in 2025, then jumped by 42.39% to -$57.8 million in 2026.
- The last three Research & Development figures came in at -$57.8 million (Q2 2026), -$25.6 million (Q1 2026), and -$100.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | -57.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.82 Mn |
| Mar 31, 2026 | -25.56 Mn |
| Dec 31, 2025 | -100.37 Mn |
| Sep 30, 2025 | -23.40 |
| Jun 30, 2025 | -44.84 Mn |
| Mar 31, 2025 | -21.14 Mn |
| Dec 31, 2024 | -83.15 Mn |
| Sep 30, 2024 | -20.70 |
| Jun 30, 2024 | -40.12 Mn |
| Mar 31, 2024 | -18.52 Mn |
| Dec 31, 2023 | -57.30 |
| Sep 30, 2023 | -20.75 Mn |
| Jun 30, 2023 | -20.90 |
| Mar 31, 2023 | -15.62 Mn |
| Dec 31, 2022 | -52.50 Mn |
| Sep 30, 2022 | -12.30 Mn |
| Dec 31, 2021 | 35.81 Mn |
| Sep 30, 2021 | -13.32 Mn |
| Dec 31, 2020 | 28.35 Mn |
| Sep 30, 2020 | -9.13 Mn |